Arylvinylazacycloalkane compounds and methods of preparation and use thereof
Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
1. A compound of the formula:
wherein:
the wavy line represents variable geometry (E or Z) about the double bond;
X is nitrogen;
R 1 is hydrogen, C 1-6 alkyl, —OR 4 , or —NR 4 R 5 ;
R 3 is hydrogen;
m is between 1 and 4;
n is between 1 and 3;
R 4 and R 5 are, independently, hydrogen or C 1-6 alkyl;
or a geometric isomer, racemic mixture, enantiomer, diastereomer, tautomer, or a pharmaceutically acceptable salt thereof.
2. The compound or claim 1 , wherein R 1 is hydrogen.
3. The compound of claim 1 , wherein n=1.
4. The compound of claim 1 , wherein m=2.
5. A compound selected from the group consisting of:
(R)- and (S)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
(R)- and (S)-5-((E)-2-piperidin-3-ylvinyl)pyrimidine
5-((E)-2-piperidin-4-ylvinyl)pyrimidine
5-((E)-2-azetidin-3-ylvinyl)pyrimidine
geometric isomers, racemic mixtures, enantiomers, and pharmaceutically acceptable salts thereof.
6. A compound selected from the group consisting of (R)- and (S)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine.
7. The compound of claim 6 , denoted (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine.